Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-10106602-B2
Application number	US-201615155815-A
Country	US
Kind code	B2
Filing date	May 16, 2016
Priority date	Jan 27, 2012
Publication date	Oct 23, 2018
Grant date	Oct 23, 2018

Abstract

Provided herein are anti-Repulsive Guidance Molecule a (RGMa) antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.

First claim

We claim:

1. An isolated monoclonal anti-Repulsive Guidance Molecule a (“RGMa”) antibody that comprises a variable heavy chain region comprising a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:2, a CDR2 comprising the amino acid sequence of SEQ ID NO:3, and a CDR3 comprising the amino acid sequence of SEQ ID NO:4, and a variable light chain region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:6, a CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a CDR3 comprising the amino acid sequence of SEQ ID NO:8 or of SEQ ID NO:73.

2. The isolated monoclonal anti-RGMa antibody of claim 1 , wherein the CDR3 of the variable light chain region comprises the amino acid sequence of SE ID NO:73.

3. The isolated monoclonal anti-RGMa antibody of claim 2 , wherein the antibody is human.

4. The isolated monoclonal anti-RGMa antibody of claim 2 , wherein the antibody comprises a heavy chain immunoglobulin constant domain of an IgG isotype.

5. The isolated monoclonal anti-RGMa antibody of claim 4 , wherein the IgG isotype is human IgG1 isotype.

6. The isolated monoclonal anti-RGMa antibody of claim 5 , wherein the human IgG1 constant domain is selected from the group consisting of SEQ ID NO:140, 141, 142 and 143.

7. The isolated monoclonal anti-RGMa antibody of claim 5 , wherein the human IgG1 constant domain comprises SEQ ID NO:143.

8. The isolated monoclonal anti-RGMa antibody of claim 2 , wherein the antibody comprises a lambda light chain constant region.

9. The isolated monoclonal anti-RGMa antibody of any one of claims 1 to 8 , wherein the antibody comprises a light chain sequence as set forth in SEQ ID NO:146 and a heavy chain sequence as set forth in SEQ ID NO:147.

10. The isolated monoclonal anti-RGMa antibody of claim 1 , wherein the antibody further comprises an agent selected from the group consisting of: an immunoadhesion molecule, an imaging agent, and a therapeutic agent, wherein the imaging agent is selected from the group consisting of a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, and biotin, and wherein the radiolabel is selected from the group consisting of 3H, 14C, 35S, 90Y, 99Tc, 111In, 125I, 131I, 177Lu, 166Ho, and 153Sm.

11. The isolated monoclonal anti-RGMa antibody of claim 2 , wherein the antibody binds to the RGMa epitope

(SEQ ID NO: 79)

PCKILKCNSEFWSATSGSHAPAS (hRGMa 47-69).

Assignees

• Abbvie Deutschland
• Abbvie Inc

Inventors

• Mueller Bernhard
• Huang Lili
• Bardwell Philip D
• Kutskova Yuliya
• Memmott John

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title